Immix Biopharma (IMMX) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 178.0% versus a loss of 33.1%. Pharming Group N.V. is the larger company by market cap ($662.5 million vs $661.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMX | PHAR |
|---|---|---|
| Share price | $7.98 | $9.36 |
| Market cap | $661.57M | $662.48M |
| 1-day change | -8.06% | -2.40% |
| YTD return | +52.58% | -47.03% |
| 1-year return | +178.05% | -33.14% |
| 5-year return | — | -0.64% |
| P/E ratio (TTM) | — | 72.00 |
| Forward P/E | — | 142.90 |
| EPS (TTM) | $-0.88 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $376.13M |
| Revenue growth (YoY) | — | +26.56% |
| Net income (latest FY) | $-29.40M | $2.85M |
| Gross margin | — | 87.90% |
| Operating margin | — | 6.87% |
| Net margin | — | 0.76% |
| 52-week high | $15.10 | $21.34 |
| 52-week low | $2.71 | $9.31 |
| Distance from 52-week high | -47.15% | -56.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +204.51% | +266.99% |
| Average volume | 1.65M | 23.08K |
| Shares outstanding | 82.90M | 70.78M |
| Employees | 21 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed PHAR by 211.2 percentage points over the past year.
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
IMMX vs PHAR FAQ
Which is bigger, Immix Biopharma or Pharming Group N.V.?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $662.48M compared with $661.57M for Immix Biopharma (IMMX).
Which stock has performed better over the past year, IMMX or PHAR?
IMMX returned +178.05% over the past 12 months, compared with -33.14% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are Immix Biopharma and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.